Tamayo Louis Edward sold $20K of LXEO

Tamayo Louis Edward (Chief Financial Officer) sold 4,117 shares of Lexeo Therapeutics, Inc. (LXEO) at $4.91 on 2026-08-18.

Original reporting
SEC EDGAR · Tamayo Louis Edward
Published Aug 19, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LXEO
Neutral
high confidence
Mentioned
$LXEO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LXEONeutralLow
01

Why it matters

The CFO's sale is modest and does not suggest material information.

02

Market read

Limited relevance; typical insider transaction with minimal market impact.

03

What to watch

Potential upcoming financing or dilution events not disclosed.

Relevance 3/10Novelty 4/10Timing: filing date 2026-08-19

Background

Form 4 filing reports insider transactions; provides transparency on insider holdings.

Company-level read

Ticker impact

$LXEONeutralHigh confidence
Context

CFO Tamayo Louis Edward sold 4,117 shares for $20,202, reducing his stake to 92,907 shares.

Expected impact

No significant impact expected.

Evidence & confidence

Sale size is small relative to market cap and typical insider activity.

Market effects

None; biotech sector unchanged.

None; US market only.

None

Counterpoint

Even small insider sells can signal concerns; monitor future filings.

Key entities

  • Lexeo Therapeutics, Inc.

    Biotech firm developing therapies.

  • Tamayo Louis Edward

    Chief Financial Officer of Lexeo Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LXEOMedAI 8/10

Lexeo Therapeutics Stock Jumps 12% On Positive Gene Therapy Data

Lexeo Therapeutics (LXEO) stock rose 12% after positive interim results from its Phase I/II HEROIC-PKP2 study of LX2020, a gene therapy for PKP2 arrhythmogenic cardiomyopathy. The therapy reduced non-sustained ventricular tachycardia by 80% and premature ventricular contractions by 44% in high-dose patients. The company reported a Q3 net loss of $38.3 million, up from $20.3 million last year, with R&D expenses increasing to $34.5 million.

$LXEOHighAI 9/10

Why is Lexeo Therapeutics stock surging today?

Lexeo Therapeutics (LXEO) stock rose 23.7% in pre-market trading after reporting positive interim data from its HEROIC-PKP2 trial for LX2020, showing 80% reduction in NSVT. The FDA indicated openness to using NSVT as a surrogate endpoint. Analysts raised price targets, with Raymond James increasing to $42. The company reported $219.1M in cash, funding operations into 2028, despite a Q3 net loss of $38.3M.